



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below

Dated 5/11/03 Signature Nabeela R. McMillan, Ph.D.

Docket No.: 01017/36370A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Souza, L.

Application No.: 09/992,873

Group Art Unit: 1646

Filed: November 6, 2001

Examiner: E. Kemmerer

For: Production of Pluripotent Granulocyte Colony-Stimulating Factor

RECEIVED

AUG 26 2003

TECH CENTER 1600/2900

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, undersigned, am an agent of record for the assignee of the above-identified application.. I certify that Amgen, Inc. a Delaware corporation, located at One Amgen Center Drive, Thousand Oaks, California, 91320-1799, is the assignee of the entire right, title, and interest in the above identified patent application, as evidenced by the attached assignment, said assignment having been recorded in the U.S. Patent and Trademark Office on February 3, 1989, at Reel 5025, Frame(s) 631.

The owner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 4,810,643, U.S. Patent No. 4,999,291, and U.S. Patent No 5,830,705. The owner hereby agrees that any patent that is granted on the above-identified application shall be enforceable only for and during such period that it and the above listed patent are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or

assignees.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminate prior to the expiration of its full statutory term.

August 19, 2003

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By: Nabeela R. McMillian
Nabeela R. McMillian, Ph.D.
Reg. No. 43,363
Attorney for Applicants